The combination adjuvant treatment of ipilimumab plus nivolumab did not meet the dual primary endpoints of the phase 3 CheckMate-915 trial, failing to improve relapse-free survival in the intent-to-treat and PD-L1 of less than 1% populations.
Patients with EGFR-positive non–small cell lung cancer who received treatment with osimertinib following surgery versus placebo experienced no clinically meaningful differences in health-related quality of life, according to results of a pivotal phase 3 trial.
Neoadjuvant atezolizumab added to nab-paclitaxel followed by doxorubicin plus cyclophosphamide improved pathologic complete responses compared with placebo plus chemotherapy in patients with early triple-negative breast cancer without adding additional treatment burden.
PreciseDx, an artificial intelligence–digital breast cancer risk discrimination platform, was able to classify patients with Oncotype Dx low-risk recurrence scores with high accuracy using only hematoxylin and eosin stain images and limited clinical data.
Data from initial dose cohorts of a phase 1/2 trial indicated the agent was found to safely drive natural killer cell proliferation in patients with high-risk myelodysplastic syndromes and acute myeloid leukemia.
The BCMA- and CD3-targeted bispecific monoclonal antibody, demonstrated early, deep, and durable responses with acceptable safety and tolerability in patients with relapsed/refractory multiple myeloma.